Natixis Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Natixis Advisors’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-37,375	Closed	-$565K	–	1534
2022 Q3	$565K	Buy	37,375 +183	+0.5%	+$2.13K	﹤0.01%	1253
2022 Q2	$279K	Sell	37,192 -220	-0.6%	-$1.55K	﹤0.01%	1398
2022 Q1	$340K	Buy	+37,412	New	+$288K	﹤0.01%	1355
2021 Q4	–	Sell	-23,803	Closed	-$271K	–	1392
2021 Q3	$271K	Sell	23,803 -259	-1%	-$3.79K	﹤0.01%	1284
2021 Q2	$385K	Sell	24,062 -385	-2%	-$6.6K	﹤0.01%	1246
2021 Q1	$436K	Sell	24,447 -1,292	-5%	-$22.3K	﹤0.01%	1184
2020 Q4	$348K	Buy	+25,739	New	+$311K	﹤0.01%	1161

Natixis Advisors's AERI Position: Q4 2022 in Review

Natixis Advisors sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 37,375 shares — an estimated $565K sold.

Natixis Advisors first reported a position in AERI in Q4 2020 and held it in 7 quarters. The position peaked at $565K in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Natixis Advisors reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Natixis Advisors sold 37,375 Aerie Pharmaceuticals shares in Q4 2022, an estimated $565K.
Natixis Advisors first reported a position in Aerie Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Natixis Advisors's Aerie Pharmaceuticals position peaked at $565K in Q3 2022.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Natixis Advisors's 13F filing for Q4 2022, filed 27 Jan 2023.